PHAS - PhaseBio ends mid-stage trial of pulmonary arterial hypertension DRUG due to COVID impacts

PhaseBio (NASDAQ:PHAS) has ended early a phase 2b trial of pemziviptadil, its pulmonary arterial hypertension candidate, due to COVID-19 impacts. The company says the pandemic has impacted manufacturing, associated drug supply, and the rate of enrollment in the study. “With the continued impact of the COVID-19 pandemic on this Phase 2b clinical trial, we believe a full evaluation of the program makes sense at this time and that any positive data generated could help galvanize support for the future development of pemziviptadil," CEO Jonathan Mow said. PhaseBio had enrolled 50% of the target population in the mid-stage trial. The company will reallocate resources to bentracimab (for reversal of ticagrelor), which is in phase 3, and other pipeline candidates, including PB6440 for resistant hypertension. Read about phase 3 data for bentracimab.

For further details see:

PhaseBio ends mid-stage trial of pulmonary arterial hypertension DRUG due to COVID impacts